News for hackers. Stuff that matters.
Re:Patient Number One in a new cancer treatment by dm319 on Thursday July 20, 2017 @05:35PM (#14816496)
That would be a sort-of holy grail of cancer therapy. The problem is that the best equipment to develop a high-affinity antibody, or find the correct T cell receptor to the mutation is the patient's immune system - and they've already done it.

Predicting what sort of antibody or T cell receptor will bind a specific mutation (more technically a piece of protein with the mutation in it - about 10 amino acids long) is hugely difficult - it requires a very good understanding of how all the amino acids fold and interact in a 3D spatial model, and we simply aren't there yet.

Your last question really depends on the mutations. Further mutations would stimulate more of an immune response, but a mutation could, for example, increase the ways a tumour cell hides from the immune system. On the other hand, it would be hard for the tumour cells to de-mutate itself to avoid TILs already specific for that mutation.

There are no comments on this comment yet.